Patient reported outcomes (PROs) are used to assess response to medication and the need for therapeutic adjustments in patients with rheumatologic disease states. Vanderbilt Specialty Pharmacy, an integrated health-system specialty pharmacy, assesses PROs through monthly refill questionnaires to guide specialty pharmacist interventions and improve patient care.

The objective of this study was to characterize the HCV cascade of care in a bridge clinic setting and identify barriers to HCV treatment in this population. This study demonstrated that several challenges and barriers exist to engage patients in HCV care in a bridge clinic model, and more strategies should be identified to engage patients and link them to care.

This study evaluated the rate and reasons for Primary Medication Nonadherence (PMN) to specialty oral oncology medications in Health System Specialty Pharmacies (HSSP). Multisite retrospective cohort study across 7 HSSP sites. Most patients (89%) prescribed oral oncology treatment at HSSP initiated therapy. Primary medication nonadherence was mostly due to patient decision.

The goal of this study was to explore healthcare providers’ experiences with specialty medications distributed via Limited Distribution Networks (LDN) that do not include IHSSPs. Participants reported barriers to navigating LDNs that can interfere with clinic workflow and patient care. IHSSPs may reduce clinic burden by helping patients access, afford, and remain on therapy.

This multisite, prospective, cohort study of patients with MS evaluated patient-reported outcomes, pharmacists' actions, and DMT adherence/persistence. Patients reported low rates of impacted productivity, hospitalization, and relapse due to MS. Pharmacists commonly provided medication education and actions to ensure DMT safety and adherence. Patients had a high rate of adherence (median PDC 88%) and persistence (86% at 12 months). Findings support positive outcomes for HSSP patients.

This study assessed the impact of pharmacist-led tailored monitoring for patients initiating encorafenib and binimetinib combination therapy. Most patients reported at least 1 AE within 14 days of initiating therapy (pre 78%, post 95%). All post-cohort patients received at least 1 pharmacist intervention. Findings support HOPA recommendations for patient follow-up within 14 days of starting a new oral anticancer therapy.